BRIEF-Erasca Says Entered Into Exclusive License Agreement With Guangzhou Joyo Pharmatech

Reuters05-17

May 16 (Reuters) - Erasca Inc :

* ERASCA INC - ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH GUANGZHOU JOYO PHARMATECH CO., LTD.

* ERASCA- UNDER DEAL CO HAS EXCLUSIVE LICENSE TO SOME PATENT OWNED BY JOYO TO DEVELOP, COMMERCIALIZE SOME PAN-RAS INHIBITORS IN ALL FIELDS OF USE

* ERASCA - UNDER AGREEMENT, CO WILL MAKE UPFRONT CASH PAYMENT TO JOYO OF $12.5 MILLION WITHIN 30 DAYS OF EFFECTIVE DATE OF JOYO LICENSE AGREEMENT

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2436801569?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-17 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2436801569","market":"us","top_or_hot":-1,"title":"BRIEF-Erasca Says Entered Into Exclusive License Agreement With Guangzhou Joyo Pharmatech","media":"Reuters","content":"<html><body><p>May 16 (Reuters) - Erasca Inc   :</p><p>   * ERASCA INC -  ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH GUANGZHOU JOYO PHARMATECH CO., LTD.</p><p>   * ERASCA- UNDER DEAL CO HAS EXCLUSIVE LICENSE TO SOME PATENT OWNED BY JOYO TO DEVELOP, COMMERCIALIZE SOME PAN-RAS INHIBITORS IN ALL FIELDS OF USE</p><p>   * ERASCA -  UNDER AGREEMENT, CO WILL MAKE UPFRONT CASH PAYMENT TO JOYO OF $12.5 MILLION WITHIN 30 DAYS OF EFFECTIVE DATE OF JOYO LICENSE AGREEMENT</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Erasca Says Entered Into Exclusive License Agreement With Guangzhou Joyo Pharmatech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Erasca Says Entered Into Exclusive License Agreement With Guangzhou Joyo Pharmatech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-17 05:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 16 (Reuters) - Erasca Inc   :   * ERASCA INC -  ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH GUANGZHOU JOYO PHARMATECH CO., LTD.   * ERASCA- UNDER DEAL CO HAS EXCLUSIVE LICENSE TO SOME PATENT ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2436801569","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2436801569","pubTimestamp":1715895872,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 16  - Erasca Inc   :   * ERASCA INC -  ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH GUANGZHOU JOYO PHARMATECH CO., LTD.   * ERASCA- UNDER DEAL CO HAS EXCLUSIVE LICENSE TO SOME PATENT OWNED BY JOYO TO DEVELOP, COMMERCIALIZE SOME PAN-RAS INHIBITORS IN ALL FIELDS OF USE   * ERASCA -  UNDER AGREEMENT, CO WILL MAKE UPFRONT CASH PAYMENT TO JOYO OF $12.5 MILLION WITHIN 30 DAYS OF EFFECTIVE DATE OF JOYO LICENSE AGREEMENTSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"简报—Erasca表示与广州卓越制药达成独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1},"content_text":"May 16 (Reuters) - Erasca Inc   :   * ERASCA INC -  ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH GUANGZHOU JOYO PHARMATECH CO., LTD.   * ERASCA- UNDER DEAL CO HAS EXCLUSIVE LICENSE TO SOME PATENT OWNED BY JOYO TO DEVELOP, COMMERCIALIZE SOME PAN-RAS INHIBITORS IN ALL FIELDS OF USE   * ERASCA -  UNDER AGREEMENT, CO WILL MAKE UPFRONT CASH PAYMENT TO JOYO OF $12.5 MILLION WITHIN 30 DAYS OF EFFECTIVE DATE OF JOYO LICENSE AGREEMENTSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2436801569"}